Skip to main content
Top
Published in: PharmacoEconomics 9/2003

01-06-2003 | Review Article

Costs of Bipolar Disorder

Authors: Dr Leah S. Kleinman, Ana Lowin, Emuella Flood, Gian Gandhi, Eric Edgell, Dennis A. Revicki

Published in: PharmacoEconomics | Issue 9/2003

Login to get access

Abstract

Bipolar disorder is a chronic affective disorder that causes significant economic burden to patients, families and society. It has a lifetime prevalence of approximately 1.3%. Bipolar disorder is characterised by recurrent mania or hypomania and depressive episodes that cause impairments in functioning and health-related quality of life. Patients require acute and maintenance therapy delivered via inpatient and outpatient treatment. Patients with bipolar disorder often have contact with the social welfare and legal systems; bipolar disorder impairs occupational functioning and may lead to premature mortality through suicide.
This review examines the symptomatology of bipolar disorder and identifies those features that make it difficult and costly to treat. Methods for assessing direct and indirect costs are reviewed. We report on comprehensive cost studies as well as administrative claims data and program evaluations. The majority of data is drawn from studies conducted in the US; however, we discuss European studies when appropriate.
Only two comprehensive cost-of-illness studies on bipolar disorder, one prevalence-based and one incidence-based, have been reported. There are, however, several comprehensive cost-of-illness studies measuring economic burden of affective disorders including bipolar disorder. Estimates of total costs of affective disorders in the US range from $US30.4–43.7 billion (1990 values). In the prevalence-based cost-of-illness study on bipolar disorder, total annual costs were estimated at $US45.2 billion (1991 values). In the incidence-based study, lifetime costs were estimated at $US24 billion.
Although there have been recent advances in pharmacotherapy and outpatient therapy, hospitalisation still accounts for a substantial portion of the direct costs. A variety of outpatient services are increasingly important for the care of patients with bipolar disorder and costs in this area continue to grow.
Indirect costs due to morbidity and premature mortality comprise a large portion of the cost of illness. Lost workdays or inability to work due to the disease cause high morbidity costs. Intangible costs such as family burden and impaired health-related quality of life are common, although it has proved difficult to attach monetary values to these costs.
Literature
1.
go back to reference Murray CJ, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press, 1996 Murray CJ, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press, 1996
2.
go back to reference Goldman HH, Rye P, Sirovatha P (editors). Mental health: a report of the Surgeon General. Washington, DC: Department of Health and Human Services, 1999 Goldman HH, Rye P, Sirovatha P (editors). Mental health: a report of the Surgeon General. Washington, DC: Department of Health and Human Services, 1999
3.
go back to reference Goodwin FK, Jamison K. Manic depressive illness. New York: Oxford University Press, 1990 Goodwin FK, Jamison K. Manic depressive illness. New York: Oxford University Press, 1990
4.
go back to reference American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151 (12 Suppl.): S1–S36 American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151 (12 Suppl.): S1–S36
5.
go back to reference Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, a division of Macmillan Inc, 1991 Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, a division of Macmillan Inc, 1991
6.
go back to reference Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8–19PubMedCrossRef Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8–19PubMedCrossRef
7.
go back to reference Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997; 27: 1079–89PubMedCrossRef Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997; 27: 1079–89PubMedCrossRef
8.
go back to reference Kovess V, Gysens S, Chanoit PF, et al. Une enquête de santé mentale: l’enquête de santé des fanciliens. Ann Med Psychol 1993; 151: 624–8 Kovess V, Gysens S, Chanoit PF, et al. Une enquête de santé mentale: l’enquête de santé des fanciliens. Ann Med Psychol 1993; 151: 624–8
9.
go back to reference Kovess V, Gysens S, Poinsard R, et al. La psychiatrie face aux problèmes sociaux: la prise en charge des RMIstes à Paris. ĽInformation Psychiatrique 1995; 3: 273–85 Kovess V, Gysens S, Poinsard R, et al. La psychiatrie face aux problèmes sociaux: la prise en charge des RMIstes à Paris. ĽInformation Psychiatrique 1995; 3: 273–85
10.
go back to reference Wittchen HU, Essau CA, von Zerssen D, et al. Lifetime and six-month prevalence of mental disorders in the Munich Follow-up Study. Eur Arch Psychiatry Clin Neurosci 1992; 241: 247–58PubMedCrossRef Wittchen HU, Essau CA, von Zerssen D, et al. Lifetime and six-month prevalence of mental disorders in the Munich Follow-up Study. Eur Arch Psychiatry Clin Neurosci 1992; 241: 247–58PubMedCrossRef
11.
go back to reference Szadoczky E, Papp Z, Vitrai J, et al. The prevalence of major depressive and bipolar disorders in Hungary: results from a national epidemiologic survey. J Affect Disord 1998; 50 (2–3): 153–62PubMedCrossRef Szadoczky E, Papp Z, Vitrai J, et al. The prevalence of major depressive and bipolar disorders in Hungary: results from a national epidemiologic survey. J Affect Disord 1998; 50 (2–3): 153–62PubMedCrossRef
12.
go back to reference Faravelli C, Guerrini Degl’Innocenti B, Aiazzi L, et al. Epidemiology of mood disorders: a community survey in Florence. J Affect Disord 1990; 20: 135–41PubMedCrossRef Faravelli C, Guerrini Degl’Innocenti B, Aiazzi L, et al. Epidemiology of mood disorders: a community survey in Florence. J Affect Disord 1990; 20: 135–41PubMedCrossRef
13.
go back to reference Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50 (2–3): 153–62 Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50 (2–3): 153–62
14.
go back to reference Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18 (1): 141–53PubMedCrossRef Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18 (1): 141–53PubMedCrossRef
15.
go back to reference Criado-Alvarez JJ, Domper Tornil JA, de la Rosa Rodriuez G. Estimate of type I bipolar disorder prevalence (1996–1998). Rev Esp Salud Publica 2000; 74 (2): 131–8PubMedCrossRef Criado-Alvarez JJ, Domper Tornil JA, de la Rosa Rodriuez G. Estimate of type I bipolar disorder prevalence (1996–1998). Rev Esp Salud Publica 2000; 74 (2): 131–8PubMedCrossRef
16.
go back to reference Canals J, Domenech E, Carbajo G, et al. Prevalence of DSM-III-R and ICD-10 psychiatric disorders in a Spanish population of 18-year-olds. Acta Psychiatr Scand 1997; 96 (4): 287–94PubMedCrossRef Canals J, Domenech E, Carbajo G, et al. Prevalence of DSM-III-R and ICD-10 psychiatric disorders in a Spanish population of 18-year-olds. Acta Psychiatr Scand 1997; 96 (4): 287–94PubMedCrossRef
17.
go back to reference Halldin J. Prevalence of mental disorder in an urban population in central Sweden. Acta Psychiatr Scand 1984; 69 (6): 503–18PubMedCrossRef Halldin J. Prevalence of mental disorder in an urban population in central Sweden. Acta Psychiatr Scand 1984; 69 (6): 503–18PubMedCrossRef
18.
go back to reference Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998; 33 (12): 587–95PubMedCrossRef Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998; 33 (12): 587–95PubMedCrossRef
19.
go back to reference van Os J, Hanssen M, Bijl RV, et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001; 58 (7): 663–8PubMedCrossRef van Os J, Hanssen M, Bijl RV, et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001; 58 (7): 663–8PubMedCrossRef
20.
go back to reference Suppes T, Dennehy EB, Wells Gibbons E. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 23–30PubMed Suppes T, Dennehy EB, Wells Gibbons E. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 23–30PubMed
21.
go back to reference Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985; 317: 1–34PubMedCrossRef Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985; 317: 1–34PubMedCrossRef
22.
go back to reference Tondo L, Baldessarini RJ. Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry 1998; 155 (10): 1434–6PubMed Tondo L, Baldessarini RJ. Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry 1998; 155 (10): 1434–6PubMed
23.
go back to reference Kessler RC. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, editor. Comorbidity in affective disorders. New York: Marcel Dekker Inc. 1999: 1–25 Kessler RC. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, editor. Comorbidity in affective disorders. New York: Marcel Dekker Inc. 1999: 1–25
24.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th, 9th ed. Washington, DC: American Psychiatric Association, 1999 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th, 9th ed. Washington, DC: American Psychiatric Association, 1999
25.
go back to reference Strakowski SM, Mauricio T, Stoll AL, et al. Comorbidity in mania at first hospitalization. Am J Psychiatry 1992; 149 (4): 554–6PubMed Strakowski SM, Mauricio T, Stoll AL, et al. Comorbidity in mania at first hospitalization. Am J Psychiatry 1992; 149 (4): 554–6PubMed
26.
go back to reference Keck PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646–52PubMed Keck PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646–52PubMed
27.
go back to reference Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 1998; 23 (6): 893–907PubMedCrossRef Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 1998; 23 (6): 893–907PubMedCrossRef
28.
go back to reference Dion GL, Tohen M, Anthony WA, et al. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry 1988; 139: 652–7 Dion GL, Tohen M, Anthony WA, et al. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry 1988; 139: 652–7
29.
go back to reference Coryell W, Scheftner W, Keller M, et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150 (5): 720–7PubMed Coryell W, Scheftner W, Keller M, et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150 (5): 720–7PubMed
30.
go back to reference Leidy NK, Palmer C, Murray M, et al. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder: psychometric performance of four self-report measures. J Affect Disord 1998; 48: 207–14PubMedCrossRef Leidy NK, Palmer C, Murray M, et al. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder: psychometric performance of four self-report measures. J Affect Disord 1998; 48: 207–14PubMedCrossRef
31.
go back to reference Cooke RG, Robb JC, Young LT, et al. Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-ITEM short form (SF-20). J Affect Disord 1996; 39: 93–7PubMedCrossRef Cooke RG, Robb JC, Young LT, et al. Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-ITEM short form (SF-20). J Affect Disord 1996; 39: 93–7PubMedCrossRef
32.
go back to reference Revicki DA, Tohen M, Gyulai L, et al. Telephone versus Inperson clinical and health status assessment interviews in patients with bipolar disorder. Harv Rev Psychiatry 1997; 5: 75–81PubMedCrossRef Revicki DA, Tohen M, Gyulai L, et al. Telephone versus Inperson clinical and health status assessment interviews in patients with bipolar disorder. Harv Rev Psychiatry 1997; 5: 75–81PubMedCrossRef
33.
go back to reference Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry 1999; 56 (10): 897–904PubMedCrossRef Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry 1999; 56 (10): 897–904PubMedCrossRef
34.
go back to reference Arnold LM, Witzeman KA, Swank ML, et al. Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population. J Affect Disord 2000; 57: 235–9PubMedCrossRef Arnold LM, Witzeman KA, Swank ML, et al. Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population. J Affect Disord 2000; 57: 235–9PubMedCrossRef
35.
go back to reference Revicki DA, Hirschfeld R, Keck P, et al. Cost-effectiveness of divalproex sodium vs lithium for bipolar disorder. Washington, DC: Mental health Services Research, 2000 Jul Revicki DA, Hirschfeld R, Keck P, et al. Cost-effectiveness of divalproex sodium vs lithium for bipolar disorder. Washington, DC: Mental health Services Research, 2000 Jul
36.
go back to reference Meeks S. Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset. J Affect Disord 1999; 52: 161–7PubMedCrossRef Meeks S. Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset. J Affect Disord 1999; 52: 161–7PubMedCrossRef
37.
go back to reference Hammen C, Gitlin M, Altshuler L. Predictors of work adjustment in bipolar I patients: a naturalistic longitudinal follow-up. J Consult Clin Psychol 2000; 68: 220–5PubMedCrossRef Hammen C, Gitlin M, Altshuler L. Predictors of work adjustment in bipolar I patients: a naturalistic longitudinal follow-up. J Consult Clin Psychol 2000; 68: 220–5PubMedCrossRef
38.
go back to reference Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999; 60: 9–21PubMedCrossRef Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999; 60: 9–21PubMedCrossRef
39.
go back to reference Dennehy EB, Suppes T. Medication algorithms for bipolar disorder. J Pract Psychiatry Behav Health 1999; 5: 142–52 Dennehy EB, Suppes T. Medication algorithms for bipolar disorder. J Pract Psychiatry Behav Health 1999; 5: 142–52
40.
go back to reference Kahn D, Frances A, Docherty J, et al. Expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996; 57 Suppl. 12A: 1–89 Kahn D, Frances A, Docherty J, et al. Expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996; 57 Suppl. 12A: 1–89
41.
go back to reference Altshuler LL, Gitlin M, Frye M, et al. Risk of depressive relapse in bipolar patients when antidepressants are discontinued. Biplor Disord 1999; 1 Suppl.: 22–3 Altshuler LL, Gitlin M, Frye M, et al. Risk of depressive relapse in bipolar patients when antidepressants are discontinued. Biplor Disord 1999; 1 Suppl.: 22–3
42.
go back to reference Goldberg IF. Treatment guidelines: current and future management of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 13: 12–7PubMed Goldberg IF. Treatment guidelines: current and future management of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 13: 12–7PubMed
43.
go back to reference Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702–9PubMed Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702–9PubMed
44.
go back to reference Tohen M, Baker RW, Alsulter L, et al. Olanzapine versus divalproex for the treatment of acute mania. The annual meeting of the European College of Neuropsychopharmacology; 2000 Sep 9–13; Munich, Germany Tohen M, Baker RW, Alsulter L, et al. Olanzapine versus divalproex for the treatment of acute mania. The annual meeting of the European College of Neuropsychopharmacology; 2000 Sep 9–13; Munich, Germany
45.
go back to reference American Psychiatric Association. The practice of electroconvulsive therapy: recommedations for treatment, training and privileging: a task force report of the American Psychiatric Association, 2nd edition. Washington DC: American Psychiatric Press, 2001 American Psychiatric Association. The practice of electroconvulsive therapy: recommedations for treatment, training and privileging: a task force report of the American Psychiatric Association, 2nd edition. Washington DC: American Psychiatric Press, 2001
46.
go back to reference Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy: the role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154: 502–9PubMed Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy: the role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154: 502–9PubMed
47.
go back to reference British Medical Association. British national formulary. 40th ed. London: BMJ Books, 2000 British Medical Association. British national formulary. 40th ed. London: BMJ Books, 2000
48.
go back to reference The Bethlem & Maudsley NHS Trust 1999. Prescribing guidelines. 5th ed. London: Dunitz M, 1999 The Bethlem & Maudsley NHS Trust 1999. Prescribing guidelines. 5th ed. London: Dunitz M, 1999
49.
go back to reference DGPPN. Behandlungsleitlinien affektive erkrankungen. Darmstadt, Steinkopf: Praxisleitlinien in Psychiatrie and Psychotherapie, 2000 DGPPN. Behandlungsleitlinien affektive erkrankungen. Darmstadt, Steinkopf: Praxisleitlinien in Psychiatrie and Psychotherapie, 2000
50.
go back to reference Vieta E. Ensayo abierte sobre la eficacia y la seguridad del topiramato en el trastorno bipolar resistente. Programa de Trastornos bipolares. (Hospital Clínic de Barcelona) (Institute de Psiquiatría) Psicologiq Clínica y Salud Mental, 1998 Nov Vieta E. Ensayo abierte sobre la eficacia y la seguridad del topiramato en el trastorno bipolar resistente. Programa de Trastornos bipolares. (Hospital Clínic de Barcelona) (Institute de Psiquiatría) Psicologiq Clínica y Salud Mental, 1998 Nov
51.
go back to reference Hess D, Ciompi L, Dauwalder HP. Nutzen- and Kosten-Evaluation eines sozialpsychiatrischen Dienstes. Nervenarzt 1986; 57 (4): 204–13PubMed Hess D, Ciompi L, Dauwalder HP. Nutzen- and Kosten-Evaluation eines sozialpsychiatrischen Dienstes. Nervenarzt 1986; 57 (4): 204–13PubMed
52.
go back to reference Reetz-Kokott U, Muller-Oerlinghausen B. Has drug treatment of manic disorders changed in clinical routine practice?: retrospective analysis of treatment modalities and results in a university psychiatric clinic. Nervenartz 1996; 67: 229–34 Reetz-Kokott U, Muller-Oerlinghausen B. Has drug treatment of manic disorders changed in clinical routine practice?: retrospective analysis of treatment modalities and results in a university psychiatric clinic. Nervenartz 1996; 67: 229–34
53.
go back to reference Licht RW, Gouliaev G, Vestergaard P, et al. Treatment of manic episodes in Scandinavia: the use of neuroleptic drugs in a clinical routine setting. J Affect Disord 1994; 32: 179–85PubMedCrossRef Licht RW, Gouliaev G, Vestergaard P, et al. Treatment of manic episodes in Scandinavia: the use of neuroleptic drugs in a clinical routine setting. J Affect Disord 1994; 32: 179–85PubMedCrossRef
54.
go back to reference Hill RG, Hardy P, Shepherd G. Perspectives on manic depression: a survey of the Manic Depression Fellowship. London, UK: The Sainsbury Centre for Mental Health, 1996 Hill RG, Hardy P, Shepherd G. Perspectives on manic depression: a survey of the Manic Depression Fellowship. London, UK: The Sainsbury Centre for Mental Health, 1996
55.
go back to reference Goodwin GM. Prophylaxis of bipolar disorder: how and who should we treat in the long term? Eur-Neuropsychopharmacol 1999; 9 Suppl. 4: S125–9PubMedCrossRef Goodwin GM. Prophylaxis of bipolar disorder: how and who should we treat in the long term? Eur-Neuropsychopharmacol 1999; 9 Suppl. 4: S125–9PubMedCrossRef
56.
go back to reference Tohen M, Waternaux CM, Tsuang MT. Outcomes in mania: a 4-year follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990; 47: 1101–6CrossRef Tohen M, Waternaux CM, Tsuang MT. Outcomes in mania: a 4-year follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990; 47: 1101–6CrossRef
57.
go back to reference Goldberg IF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152 (3): 379–84PubMed Goldberg IF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152 (3): 379–84PubMed
58.
go back to reference Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 35–40PubMed Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 35–40PubMed
59.
go back to reference Harrow M, Goldberg IF, Grossman LS, et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665–71PubMedCrossRef Harrow M, Goldberg IF, Grossman LS, et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665–71PubMedCrossRef
60.
go back to reference O’Connell RA, Mayo JA, Flatow L, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123–9PubMedCrossRef O’Connell RA, Mayo JA, Flatow L, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123–9PubMedCrossRef
61.
go back to reference Tsuang MT, Dempsey GM. Long-term outcome of major psychoses: II. schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1997; 36 (12): 1302–4CrossRef Tsuang MT, Dempsey GM. Long-term outcome of major psychoses: II. schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1997; 36 (12): 1302–4CrossRef
62.
go back to reference Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder: demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1992; 49: 126–31PubMedCrossRef Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder: demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1992; 49: 126–31PubMedCrossRef
63.
65.
go back to reference Kessler RC. The national comorbidity survey of the United States. Int Rev Psychiatry 1994; 6: 8–19CrossRef Kessler RC. The national comorbidity survey of the United States. Int Rev Psychiatry 1994; 6: 8–19CrossRef
66.
go back to reference Walsh E, Harvey K, White I, et al. Prevalence and predictors of parasuicide in chronic psychosis. UK700 group. Acta Psychiatr Scand 1999; 100 (5): 375–82PubMedCrossRef Walsh E, Harvey K, White I, et al. Prevalence and predictors of parasuicide in chronic psychosis. UK700 group. Acta Psychiatr Scand 1999; 100 (5): 375–82PubMedCrossRef
67.
68.
go back to reference Ahrens B, Berghofer A, Wolf T, et al. Suicide attempts, age and duration of illness in recurrent affective disorders. J Affect Disord 1995; 36: 43–9PubMedCrossRef Ahrens B, Berghofer A, Wolf T, et al. Suicide attempts, age and duration of illness in recurrent affective disorders. J Affect Disord 1995; 36: 43–9PubMedCrossRef
69.
go back to reference Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59 (8): 405–14PubMedCrossRef Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59 (8): 405–14PubMedCrossRef
70.
go back to reference Thies-Flecthner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 102–7 Thies-Flecthner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 102–7
71.
go back to reference Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39: 21–36PubMed Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39: 21–36PubMed
72.
go back to reference Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of major health impairments. Lexington (MA): Lexington Books, 1981 Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of major health impairments. Lexington (MA): Lexington Books, 1981
73.
go back to reference Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental health illness: 1985. Report submitted to the Office of Financing and Coverage Policy of the Alcohol, Drug Abuse and Mental Health Administration, US Department of Health and Human Services. San Francisco (CA): Institute for Health & Aging, University of California, 1990 Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental health illness: 1985. Report submitted to the Office of Financing and Coverage Policy of the Alcohol, Drug Abuse and Mental Health Administration, US Department of Health and Human Services. San Francisco (CA): Institute for Health & Aging, University of California, 1990
74.
go back to reference Hodgson TA, Meiners M. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–62PubMedCrossRef Hodgson TA, Meiners M. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–62PubMedCrossRef
75.
go back to reference Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983; 4: 129–64PubMed Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983; 4: 129–64PubMed
76.
go back to reference Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–18PubMed Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–18PubMed
77.
go back to reference Clark RE, Teague GB, Ricketts SK, et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorder. Health Serv Res 1998; 33: 1285–308PubMed Clark RE, Teague GB, Ricketts SK, et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorder. Health Serv Res 1998; 33: 1285–308PubMed
78.
go back to reference Quinliven R, Hough R, Crowell A, et al. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatr Serv 1995; 46: 365–71 Quinliven R, Hough R, Crowell A, et al. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatr Serv 1995; 46: 365–71
79.
go back to reference Rice DP, Miller LS. The economic burden of affective disorders. Adv Health Econ Health Serv Res 1993; 14: 37–53PubMed Rice DP, Miller LS. The economic burden of affective disorders. Adv Health Econ Health Serv Res 1993; 14: 37–53PubMed
80.
go back to reference Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 213–9PubMed Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 213–9PubMed
81.
go back to reference Begley CE, Annegers IF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001; 19 (5 Pt 1): 483–95PubMedCrossRef Begley CE, Annegers IF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001; 19 (5 Pt 1): 483–95PubMedCrossRef
82.
go back to reference Johnstone B, Loosbrock DL, Morris LS, et al. Estimated costs of treatment for bipolar disorder in a large employer database. The 128th Annual Meeting of APHA; 2000 Nov 14; Boston (MA) Johnstone B, Loosbrock DL, Morris LS, et al. Estimated costs of treatment for bipolar disorder in a large employer database. The 128th Annual Meeting of APHA; 2000 Nov 14; Boston (MA)
83.
go back to reference Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999; 50 (10): 1303–8PubMed Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999; 50 (10): 1303–8PubMed
84.
go back to reference Jonsson B, Bebbington PE. What price depression?: the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73PubMedCrossRef Jonsson B, Bebbington PE. What price depression?: the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73PubMedCrossRef
85.
go back to reference Amaddeo F, Beecham J, Bonizzato P, et al. The costs of community-based psychiatric care for first-ever patients: a case register study. Psychol Med 1998; 28 (1): 173–83PubMedCrossRef Amaddeo F, Beecham J, Bonizzato P, et al. The costs of community-based psychiatric care for first-ever patients: a case register study. Psychol Med 1998; 28 (1): 173–83PubMedCrossRef
86.
go back to reference Amaddeo F, Bonizzato P, Tansella M. Psychiatric case registers for monitoring service utilization and evaluating its costs. In: Il Pensiero Scientifico, Tansella M, editor. Making rational mental health services. Roma: 1997: 177–98 Amaddeo F, Bonizzato P, Tansella M. Psychiatric case registers for monitoring service utilization and evaluating its costs. In: Il Pensiero Scientifico, Tansella M, editor. Making rational mental health services. Roma: 1997: 177–98
87.
go back to reference Dardennes R, Lafuma A, Watkins S. Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine. Encephale 1999; 25 (5): 391–400PubMed Dardennes R, Lafuma A, Watkins S. Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine. Encephale 1999; 25 (5): 391–400PubMed
88.
go back to reference A history of mental health and community care. London, UK: MIND, 2000 A history of mental health and community care. London, UK: MIND, 2000
89.
go back to reference Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281–94PubMedCrossRef Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281–94PubMedCrossRef
90.
go back to reference Narrow WE, Regier DA, Rae DS, et al. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry 1993; 50: 95–107PubMedCrossRef Narrow WE, Regier DA, Rae DS, et al. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry 1993; 50: 95–107PubMedCrossRef
91.
go back to reference Hospital episode statistics. 1996/97. London, Department of Health, 2000 Hospital episode statistics. 1996/97. London, Department of Health, 2000
92.
go back to reference AOK-Bundesverband, editor. AOK-Bundesverband. Krankheitsartenstatistik 1997. Bonn: Krankheitsartenstatistik, 1999 AOK-Bundesverband, editor. AOK-Bundesverband. Krankheitsartenstatistik 1997. Bonn: Krankheitsartenstatistik, 1999
93.
go back to reference Scottish Morbidity Record 1. 1997/98. NHS Scotland: Information and Statistics Division, 2000 Scottish Morbidity Record 1. 1997/98. NHS Scotland: Information and Statistics Division, 2000
94.
go back to reference Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8PubMedCrossRef Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8PubMedCrossRef
95.
go back to reference Royal College of General Practitioners and Office of Population Censuses and Surveys. Morbidity statistics from general practice: fourth national study 1991–1992. London: HMSO, 1995 Royal College of General Practitioners and Office of Population Censuses and Surveys. Morbidity statistics from general practice: fourth national study 1991–1992. London: HMSO, 1995
96.
go back to reference Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000; 61 Suppl. 13: 38–41PubMed Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000; 61 Suppl. 13: 38–41PubMed
97.
go back to reference Galvin PM, Knezek LD, Rush AJ, et al. Clinical and economic impact of newer versus older antipsychotic medication in a community mental health center. Clin Ther 1999; 22 (6): 1105–16CrossRef Galvin PM, Knezek LD, Rush AJ, et al. Clinical and economic impact of newer versus older antipsychotic medication in a community mental health center. Clin Ther 1999; 22 (6): 1105–16CrossRef
98.
go back to reference Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173 Suppl. 34: 4–9 Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173 Suppl. 34: 4–9
99.
go back to reference Franks DD. Economics contribution of families for persons with severe and persistent mental illness. Adm Policy Ment Health 1990; 18: 9–12CrossRef Franks DD. Economics contribution of families for persons with severe and persistent mental illness. Adm Policy Ment Health 1990; 18: 9–12CrossRef
100.
go back to reference OFISALUD and Bernard Krieff Sociological Studies Office. El coste social de los trastornos de salud mental en España. SmithKline Beecham Pharmaceuticals, 1998 OFISALUD and Bernard Krieff Sociological Studies Office. El coste social de los trastornos de salud mental en España. SmithKline Beecham Pharmaceuticals, 1998
101.
go back to reference Keck PE, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of Divalproex vs Lithium in the acute and prophylactic treatment of bipolar disorder. J Clin Psychiatry 1996; 57 (5): 213–22PubMed Keck PE, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of Divalproex vs Lithium in the acute and prophylactic treatment of bipolar disorder. J Clin Psychiatry 1996; 57 (5): 213–22PubMed
102.
go back to reference Baker CB, Woods SW, Sernyak MI. Cost-effectiveness of divalproex versus lithium [letter]. J Clin Psychiatry 1997, 58 (8): 363PubMedCrossRef Baker CB, Woods SW, Sernyak MI. Cost-effectiveness of divalproex versus lithium [letter]. J Clin Psychiatry 1997, 58 (8): 363PubMedCrossRef
103.
go back to reference Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Pharmacol Bull 1995; 31: 57–65 Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Pharmacol Bull 1995; 31: 57–65
104.
go back to reference Revicki DA, Paramore CL, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003; 64: 288–94PubMedCrossRef Revicki DA, Paramore CL, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003; 64: 288–94PubMedCrossRef
105.
go back to reference Namjoshi M, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: results from a randomized controlled trial. J Affect Disord 2001; 69: 109–18CrossRef Namjoshi M, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: results from a randomized controlled trial. J Affect Disord 2001; 69: 109–18CrossRef
106.
go back to reference Sanger T, Namjoshi M, Gibson P, et al. Long-term olanzapine therapy in the stabilization and maintenance treatment of bipolar I disorder: an open label continuation phase study. J Clin Psychiatry 2001; 62: 273–81PubMedCrossRef Sanger T, Namjoshi M, Gibson P, et al. Long-term olanzapine therapy in the stabilization and maintenance treatment of bipolar I disorder: an open label continuation phase study. J Clin Psychiatry 2001; 62: 273–81PubMedCrossRef
Metadata
Title
Costs of Bipolar Disorder
Authors
Dr Leah S. Kleinman
Ana Lowin
Emuella Flood
Gian Gandhi
Eric Edgell
Dennis A. Revicki
Publication date
01-06-2003
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2003
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200321090-00001

Other articles of this Issue 9/2003

PharmacoEconomics 9/2003 Go to the issue